The majority of engineered αβTCRs recognize epitopes presented by MHC molecules, thereby narrowing down the group of potential targets to those which are MHC-restricted, and exhibit an increased specificity recognition and affinity for tumor cells (Figure 1A) (32, 33). Here, HLA-C is linked to neoplasm.